AAV9-cBIN1 gene therapy rescues chronic heart failure due to ischemic cardiomyopathy in a canine model.

Commun Med (Lond) · 2025 · PMC11950290 · PMID 40148575

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

1292 ± 317 pmol/L, p = 0.4968) and by five weeks post-therapy, the NT-proBNP of the AAV9-cBIN1 -treated group decreased (improved) significantly (1007 ± 374 pmol/L, p = 0.0473), and NT-proBNP of the AAV9-GFP- treated group increased (worsened) (1451 ± 769 pmol/L, p = 0.0812), although did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.